Drug Profile
TEI-A
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antigouts; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout; Hyperuricaemia
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Gout in Japan (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Hyperuricaemia in Japan (PO)
- 03 Nov 2017 Preclinical trials in Hyperuricaemia and Gout in Japan (PO) before November 2017